Compare UPBD & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | MLTX |
|---|---|---|
| Founded | 1986 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | N/A |
| Metric | UPBD | MLTX |
|---|---|---|
| Price | $19.81 | $15.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $32.25 | $22.22 |
| AVG Volume (30 Days) | 631.5K | ★ 1.4M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 7.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $4,577,844,000.00 | N/A |
| Revenue This Year | $10.33 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | ★ 7.48 | N/A |
| 52 Week Low | $15.82 | $5.95 |
| 52 Week High | $30.20 | $62.75 |
| Indicator | UPBD | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 52.03 |
| Support Level | $19.40 | $14.47 |
| Resistance Level | $20.84 | $16.15 |
| Average True Range (ATR) | 0.74 | 0.79 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 54.62 | 54.63 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.